Matinas BioPharma (MTNB) shelved development of a prescription formulation of fish oil three years ago. The tiny company, with a stock that trades for pennies, decided investors would be more interested in its drug delivery technology and a small pipeline of anti-infectives.

But then Amarin (AMRN) happened. Amarin’s stock price soared to all-time highs — adding nearly $5 billion in market cap — on the readout of a large clinical trial showing its proprietary fish oil drug, called Vascepa, cut the risk of bad cardiovascular events like heart attacks and stroke in patients by an astounding 25 percent.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I am sure that there is nothing to prove. Fish oil is useless against heart diseases. It’s a myth that fish oil is so universal. I don’t believe Amarin. They gain money only.

  • I follow the news after Amarin. It’s all very interesting about Vascepa. Fish oil they are positioned as purified. Clinical trials are highly questionable. Amarin employees participated Vascepa’s clinical trials. In general, the company has raised the hype in the press, the stock cost has rised.

    • I am sure that there is nothing to prove. Fish oil is useless against heart diseases. It’s a myth that fish oil is so universal. I don’t believe Amarin. They gain money only .

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy